News headlines about IDEXX Laboratories (NASDAQ:IDXX) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news impact score of 0.04 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.8051324626285 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
NASDAQ:IDXX traded down $2.43 during trading hours on Friday, reaching $191.78. 301,021 shares of the company were exchanged, compared to its average volume of 464,403. The company has a market capitalization of $16,908.30, a P/E ratio of 58.47, a P/E/G ratio of 2.38 and a beta of 0.59. IDEXX Laboratories has a 1-year low of $146.09 and a 1-year high of $207.14. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.58 earnings per share. sell-side analysts anticipate that IDEXX Laboratories will post 4.11 EPS for the current fiscal year.
IDXX has been the topic of a number of recent research reports. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Piper Jaffray initiated coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 target price on the stock. Canaccord Genuity reiterated a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Bank of America increased their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. IDEXX Laboratories has a consensus rating of “Buy” and an average price target of $194.00.
In related news, VP Brian P. Mckeon sold 6,602 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the sale, the vice president now owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel M. Junius sold 2,974 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $190.06, for a total value of $565,238.44. Following the sale, the director now directly owns 5,602 shares in the company, valued at approximately $1,064,716.12. The disclosure for this sale can be found here. Insiders have sold 71,576 shares of company stock worth $12,860,017 in the last three months. 2.56% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “IDEXX Laboratories (IDXX) Receiving Somewhat Positive Media Coverage, Study Finds” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/15/idexx-laboratories-idxx-receiving-somewhat-positive-media-coverage-study-finds.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.